Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLID.L Regulatory News (LID)

  • There is currently no data for LID

LiDCO Extends Collaboration With BD

16 Apr 2009 07:00

RNS Number : 6366Q
LiDCO Group Plc
15 April 2009
 



Press Release 

16 April 2009

LiDCO Group Plc

("LiDCO" or "the Company")

LiDCO extends collaboration with BD

LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, today has extended its exclusive collaboration with BD (Becton, Dickinson and Company)a leading global medical technology company dedicated to helping all people live healthy lives (see www.bd.com).

In June 2007, LiDCO signed an exclusive UK marketing collaboration with Becton, Dickinson U.K. LimitedLiDCO today announces the expansion of this exclusive collaboration with BD. Under the amended and restated terms of the agreement, LiDCO and BD will extend their exclusive marketing collaboration to include additional territories. The collaboration provides that BD Medical - Medical Surgical Systems regional sales teams will provide sales and marketing support for LiDCO products in territories additional to the UK. This marketing collaboration will result in an enhanced product offering for BD's customers as well as superior sales coverage for both LiDCO and LiDCO's network of distributors. 

In a separate agreement, LiDCO have entered an exclusive distribution and sales relationship for the LiDCOrapid Monitor with BD in Japan. This relationship will result in an enhanced product offering for BD customers, as well as improved access to LiDCO's technology by Japanese clinicians and patients. 

Dr Terry O'Brien, Chief Executive of LiDCO, commenting on the agreements stated: "This licensing arrangement in Japan and expansion of our marketing collaboration with a major corporation of the stature of BD further enhances our capabilities to provide our acute care customers with the best possible products and services to improve outcomes and reduce complications such as infections. We are very pleased to share a commitment with BD towards expanding access to innovative technologies that improve outcomes in the critically ill." 

Hideyuki Ashikaga, President, BD in Japan stated:

"BD designs and markets innovative products that address significant healthcare problems and deliver demonstrably higher benefits to patients, healthcare workers and researchers. Collaborating with LiDCO, an innovative company in an important healthcare market, will reinforce our capabilities to serve that market, in line with our corporate purpose of 'Helping all people live healthy lives'".

- ENDS -

For more information please contact:

LiDCO Group Plc

Terry O'Brien - Chief Executive

John Rowland - Company Secretary

Tel: +44 (0)20 7749 1500

www.lidco.com

FinnCap

Geoff Nash/ Stephen Norcross/

Marc Young 

+44 (0)20 7600 1658

www.finncap.com 

Media enquiries

Abchurch Communications

Heather Salmond / Stephanie Cuthbert / Simone Alves 

+44 (0)20 7398 7728

www.abchurch-group.com

About LiDCO Group Plc

LiDCO is a leading supplier of minimally invasive hemodynamic monitoring equipment and disposables. These are used primarily for the management of hospital patients requiring critical care or at major cardiovascular risk. LiDCO's computer-based technology significantly reduces the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London. LiDCO is based in the UK and its shares are traded on AIM. For more information please see www.lidco.com.

The Company's manufacturing facility is in Hoxton, London, and its current products are:

* LiDCOplus is a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%)

* LiDCOrapid: our new cardiac output monitor designed specifically for use in the Operating Theatre for fluid and drug management at the point of care. The monitor features many clinical benefits. These enable acute-care physicians to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being during and after surgery. 

Early and rapid warning of change

Clear indication of therapeutic route: fluid or drug

Quantification of hemodynamic response, particularly stroke volume

Permits more effective delivery of fluids - the right amount at the right time

Advanced hemodynamic care has been shown to:

- Contribute to reduced morbidity and complications

- Reduce length of stay

- Reduce overall cost of care

* LiDCO single-patient-use disposables used in conjunction with the LiDCOplus and LiDCOrapid Monitors. 

LiDCOview: an easy-to-use graphical display of historical LiDCOplus hemodynamic data. Both clinical researchers and routine users can view beat-to-beat hemodynamic data collected with the LiDCOplus. LiDCOviewSE is the standard version of this tool and is available for free, allowing anyone to download and access data from the LiDCOplus. LiDCOviewPRO is the Professional version, allowing users to analyse, export and report the LiDCOplus data. A free trial of LiDCOviewPRO is available for evaluation purposes prior to purchase

LiDCO Distribution Network:

The Company sells direct to hospitals in the UK, and elsewhere predominantly through a worldwide network of specialty critical care and anesthesia distributors.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCIAMFTMMJBBML
Date   Source Headline
14th Feb 20181:15 pmRNSHolding(s) in Company
1st Feb 20187:00 amRNSBlock Listing Review
17th Jan 20187:00 amRNSJapan registration &appointment of new distributor
15th Jan 201810:06 amRNSHolding(s) in Company
13th Dec 20174:33 pmRNSHolding(s) in Company
22nd Nov 20179:28 amRNSHolding(s) in Company
10th Oct 20177:00 amRNSHalf-year Report
10th Aug 20177:01 amRNSTrading update & Notice of results
10th Aug 20177:00 amRNSFirst High Usage Programme Account in US
1st Aug 20177:00 amRNSBlock Listing Review
25th Jul 20174:37 pmRNSHolding(s) in Company
6th Jul 20177:00 amRNSConfirmation of CFO appointment & Award of options
8th Jun 20177:00 amRNSInvestor presentation
7th Jun 20177:00 amRNSUS FDA clearance for LiDCOunity v2
10th May 201711:35 amRNSResult of AGM
10th May 20177:00 amRNSAGM Statement
9th May 20177:00 amRNSNew LiDCOunity v2 monitor launch
4th May 20177:00 amRNSLaunch of new website
28th Apr 20177:00 amRNSHolding(s) in Company
20th Apr 20177:00 amRNSAward of share options/ director dealing
3rd Apr 20177:00 amRNSInvestor presentation
3rd Apr 20177:00 amRNSDirector/PDMR Shareholding
28th Mar 20177:00 amRNSFinal Results
13th Mar 20177:00 amRNSNotice of Results
1st Mar 20177:00 amRNSBoard Changes
16th Feb 201710:07 amRNSHolding(s) in Company
14th Feb 20177:00 amRNSTrading update and notice of results
3rd Feb 20177:00 amRNSHolding(s) in Company
19th Jan 201710:29 amRNSHoldings in Company
18th Jan 20177:00 amRNSHolding(s) in Company
10th Jan 20177:00 amRNSAppointment of Head of North America
3rd Jan 20171:03 pmRNSHolding(s) in Company
3rd Jan 201712:31 pmRNSHolding(s) in Company
3rd Jan 201712:30 pmRNSHolding(s) in Company
23rd Dec 201610:23 amRNSResult of GM, TVR and Transactions by PDMRs
7th Dec 20167:00 amRNSProposed Placing & Notice of General Meeting
11th Oct 20167:00 amRNSHalf-year Report
20th Sep 20167:00 amRNSNotice of Results
8th Sep 20167:00 amRNSFurther clinical support for LiDCOrapid
7th Sep 20163:46 pmRNSHolding(s) in Company
11th Aug 20167:01 amRNSAppointment of Non Executive Director
11th Aug 20167:00 amRNSTrading update and notice of results
1st Jun 20169:17 amRNSHolding(s) in Company
25th May 201612:28 pmRNSResult of AGM
25th May 20167:00 amRNSAGM Statement
16th May 20167:00 amRNSUS Distribution Agreement with ICU Medical
6th May 20167:00 amRNSNotice of AGM
21st Apr 20167:00 amRNSUS launch of new LiDCOunity monitor
4th Apr 20167:00 amRNSUS FDA 510k clearance for LiDCOunity
30th Mar 201611:23 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.